The federal government is investing millions of new dollars to boost Canada’s domestic vaccine and drug development capacity.
Innovation Minister Francois-Philippe Champagne says Canada must build and expand homegrown biomanufacturing facilities and develop more equipment to secure more vaccines and therapeutics to combat COVID-19.
Ottawa will contribute up to $54.2 million to KABS Laboratories and up to $13.44 million to Immune Biosolutions to expand their respective operations in Quebec.
It will also provide up to $32.7 million to Novocol Pharmeceutical of Canada for growth of its biomanufacturing facilities in Ontario.
Ottawa is also investing $150 million to help companies advance through the early stages of research and development of several Canadian-made vaccine candidates.
- Wandering toddler spotted on busy road after escaping crib, walking out door: Ontario police
- As wildfires raise water bomber demand, experts concerned about aging fleets
- Canada’s drug pricing conflict sparked by health minister letter, emails show
- Call the influencers: How the CDIC tried to quell fears after SVB’s collapse